Avid Bioservices Inc (CDMO)

[geocappy1]

IMO we are looking better every day. If we make it to the ESMO w/o triggering the 2nd line MOS or the 1st line lung cancer trial MOS, the proof of concept continues to build as data results back up the MOA of Bavi.

At that point it is hard to deny that bavi has efficacy. We would be at 14-15.5 months for 2nd line MOS, 15-16.5months for 1st line (if math correct) and IMO we probably show efficacy in the HepC trial (slower working).

Seems to me it won't be if a partner wants to partner but how to structure an agreement on the value that is fair to both parties.